IL308755A - T cell receptors targeting ras mutations and uses thereof - Google Patents

T cell receptors targeting ras mutations and uses thereof

Info

Publication number
IL308755A
IL308755A IL308755A IL30875523A IL308755A IL 308755 A IL308755 A IL 308755A IL 308755 A IL308755 A IL 308755A IL 30875523 A IL30875523 A IL 30875523A IL 308755 A IL308755 A IL 308755A
Authority
IL
Israel
Prior art keywords
cell receptors
ras mutations
receptors targeting
targeting ras
mutations
Prior art date
Application number
IL308755A
Other languages
English (en)
Hebrew (he)
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL308755A publication Critical patent/IL308755A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL308755A 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof IL308755A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192783P 2021-05-25 2021-05-25
PCT/US2022/030814 WO2022251283A1 (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Publications (1)

Publication Number Publication Date
IL308755A true IL308755A (en) 2024-01-01

Family

ID=84230235

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308755A IL308755A (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Country Status (11)

Country Link
US (1) US20240091361A1 (https=)
EP (1) EP4347639A4 (https=)
JP (1) JP2024520427A (https=)
KR (1) KR20240013750A (https=)
CN (1) CN117545766A (https=)
AU (1) AU2022283277A1 (https=)
BR (1) BR112023024595A2 (https=)
CA (1) CA3219923A1 (https=)
IL (1) IL308755A (https=)
MX (1) MX2023014073A (https=)
WO (1) WO2022251283A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
AU2024228388A1 (en) * 2023-02-27 2025-10-02 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024339041A1 (en) * 2023-09-05 2026-04-16 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen
WO2025137468A1 (en) * 2023-12-22 2025-06-26 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
CA3116749A1 (en) * 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途

Also Published As

Publication number Publication date
EP4347639A1 (en) 2024-04-10
CN117545766A (zh) 2024-02-09
WO2022251283A1 (en) 2022-12-01
AU2022283277A1 (en) 2023-12-14
BR112023024595A2 (pt) 2024-02-15
EP4347639A4 (en) 2025-08-06
CA3219923A1 (en) 2022-12-01
US20240091361A1 (en) 2024-03-21
MX2023014073A (es) 2024-02-21
JP2024520427A (ja) 2024-05-24
AU2022283277A9 (en) 2024-01-04
KR20240013750A (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
IL308755A (en) T cell receptors targeting ras mutations and uses thereof
IL272069A (en) Dosage regimens of anti-lag-3 antibodies and uses thereof
EP3712151A4 (en) AROMATIC SPIRO CYCLIC COMPOUND AND ASSOCIATED USE
EP3706803A4 (en) CONJUGATES BASED ON A BIOMOLECULE AND THEIR USE
EP3638207C0 (en) NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND THEIR USES
EP3886870A4 (en) Nanoparticles containing cellular membrane and uses thereof
EP3974452A4 (en) Fully human antibody targeting cd19 and application thereof
EP3820467A4 (en) ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
DK3388427T3 (da) Derivater af dolastatin 10 og auristatiner
EP3959307A4 (en) Engineered cells and uses thereof
EP3732203A4 (en) ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1
EP4359442A4 (en) ANTI-CCR8 ANTIBODIES AND THEIR USES
EP3623467A4 (en) HIGHLY ACTIVE NK CELL AND ITS USE
EP4444324A4 (en) MODIFIED T CELL RECEPTORS AND THEIR USES
EP4342532C0 (en) Antiplatelet drugs and their uses
PL3618848T3 (pl) Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne
PL3710485T3 (pl) Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania
EP4301784A4 (en) Antibodies against claudin-6 and uses thereof
EP4142793A4 (en) ABCB5-SPECIFIC ANTIBODIES AND THEIR USES
EP3541378A4 (en) ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE MITIGATION OF PROTEINOPATHIES
EP4244255A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP4437002A4 (en) ANTI-HSP90 ANTIBODY? AND ITS USES
EP4132569A4 (en) ANTI-PHF-TAU ANTIBODIES AND USES
EP4330275A4 (en) Chimeric receptors targeting Adgre2 and/or Clec12A and their uses
EP3672798A4 (en) MEMBERSHIP PROMOTERS AND THEIR USE